Clinical trial
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
NCT00428610 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2007
- Completion date
- January 31, 2012
- Enrollment
- 103 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube cancer, ovarian cancer, primary peritoneal cancer